Lipocine announces positive results for LPCN 1144 treatment in NASH

Lipocine announces positive results for LPCN 1144 treatment in NASH

Lipocine announced positive results from its phase 2 proof of concept study that investigated LPCN 1144, an orally delivered prodrug of endogenous testosterone, in the treatment of nonalcoholic steatohepatitis, according to a press release.The Liver Fat intervention with oral Testosterone (LiFT) clinical study comprised 37 men with NASH dosed twice daily with either 142 mg testosterone equivalent (n = 13), 142 mg testosterone equivalent formulated with 238 mg of d-alpha tocopherol equivalent (n = 13) or matching placebo (n = 11). Studied endpoints included change in hepatic fat fraction afterRead More

Share on facebook
Share on twitter
Share on linkedin